Analyst Rating Update on Antares Pharma (ATRS)

Antares Pharma (NASDAQ:ATRS) : 3 brokerage houses believe that Antares Pharma (NASDAQ:ATRS) is a Strong Buy at current levels. Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 3 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Antares Pharma (NASDAQ:ATRS): stock turned positive on Tuesday. Though the stock opened at $1.05, the bulls momentum made the stock top out at $1.14 level for the day. The stock recorded a low of $1.05 and closed the trading day at $1.11, in the green by 5.71%. The total traded volume for the day was 1,205,503. The stock had closed at $1.05 in the previous days trading.

In an insider trading activity, Graham Peter J, officer (SVP General Counsel, Secretary) of Antares Pharma, Inc., executed a transaction worth $15,400 on March 21, 2016. A total of 20,000 shares were purchased at an average price of $0.77. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.